Tenax Therapeutics (TENX) Stock Price, News & Analysis

Company Overview

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing treatments for cardiovascular and pulmonary diseases with significant unmet medical needs. The company’s research and development activities are centered on therapies intended to improve outcomes for patients with conditions affecting the heart and lungs.

Tenax’s primary product candidate is an oral formulation of levosimendan, a drug designed to enhance cardiac contractility and produce vasodilatory effects. The company has been evaluating the therapy, also referred to as TNX-103, for pulmonary hypertension associated with heart failure with preserved ejection fraction, a condition for which treatment options remain limited.

The company conducts its development activities primarily in the United States and has focused on advancing levosimendan through clinical development and regulatory review. Tenax Therapeutics was formerly known as Oxygen Biotherapeutics and adopted its current name in 2015. The company is headquartered in Morrisville, North Carolina, and its common stock trades on the Nasdaq under the symbol TENX.

Key Stats

• Today's Range: $1.80 to $1.91
• 50-Day Range: $1.38 to $14.33
• 52-Week Range: $1.31 to $19.40
• Volume: 2.34 million shs
• Average Volume: 2.54 million shs
• Market Capitalization: $69.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Hold

Tenax Therapeutics Stock Analysis - MarketRank™

Tenax Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 315th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Tenax Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 3 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

Tenax Therapeutics has a consensus price target of $14.00, representing about 648.7% upside from its current price of $1.87.

Amount of Analyst Coverage

Tenax Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tenax Therapeutics are expected to decrease in the coming year, from ($1.38) to ($1.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tenax Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tenax Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tenax Therapeutics has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.52% of the float of Tenax Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tenax Therapeutics has a short interest ratio ("days to cover") of 2.35, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tenax Therapeutics has recently increased by 30.49%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tenax Therapeutics does not currently pay a dividend.

Dividend Growth

Tenax Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Tenax Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Tenax Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for TENX on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Tenax Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.0 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Tenax Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $4,922,089.00 in company stock, which represents 7.0333% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Tenax Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,922,089.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.81% of the stock of Tenax Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

1.67% of the stock of Tenax Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 7/31/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TENX
• CIK: 34956
• Web: www.tenaxthera.com
• Phone: 919-855-2100
• Fax: 919-855-2133
• Employees: 16
• Year Founded: 1967

Price Target and Rating

• Average Price Target for Tenax Therapeutics: $14.00
• High Price Target: $50.00
• Low Price Target: $4.00
• Potential Upside/Downside: +648.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -61.54%
• Return on Assets: -57.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.07
• Quick Ratio: 15.07

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.42 per share
• Price / Book: 0.18

Miscellaneous

• Outstanding Shares: 37,424,000
• Free Float: 33,378,000
• Market Cap: $69.98 million
• Optionable: Not Optionable
• Beta: 0.92